AR033465A1 - THE USE OF AN ENDOTHELINE RECEIVER ANTAGONIST IN THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT IN THE FAVORABLE MODULATION OF HEALTH-RELATED QUALITY AND TEMPORARY PROGRESSION ADJUSTED TO QUALITY RELATED TO HEALTH OF A PATIENT DISEASE - Google Patents

THE USE OF AN ENDOTHELINE RECEIVER ANTAGONIST IN THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT IN THE FAVORABLE MODULATION OF HEALTH-RELATED QUALITY AND TEMPORARY PROGRESSION ADJUSTED TO QUALITY RELATED TO HEALTH OF A PATIENT DISEASE

Info

Publication number
AR033465A1
AR033465A1 ARP020101335A ARP020101335A AR033465A1 AR 033465 A1 AR033465 A1 AR 033465A1 AR P020101335 A ARP020101335 A AR P020101335A AR P020101335 A ARP020101335 A AR P020101335A AR 033465 A1 AR033465 A1 AR 033465A1
Authority
AR
Argentina
Prior art keywords
health
quality
adjusted
endotheline
manufacture
Prior art date
Application number
ARP020101335A
Other languages
Spanish (es)
Inventor
Singh Robert J Padley Amitabh
Ashraf Talat
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/832,752 external-priority patent/US20030022811A1/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR033465A1 publication Critical patent/AR033465A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Método para modular favorablemente la calidad de vida relacionada con la salud y la progresion temporal de una enfermedad ajustada a la calidad relacionado con la salud en un paciente con cáncer de prostata y un método par medir la progresion temporal de la enfermedad ajustada a la calidad relacionada con la salud.Method to favorably modulate the health-related quality of life and the temporal progression of a health-related quality-related disease in a patient with prostate cancer and a method to measure the temporal progression of the disease adjusted to the related quality With health.

ARP020101335A 2001-04-11 2002-04-11 THE USE OF AN ENDOTHELINE RECEIVER ANTAGONIST IN THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT IN THE FAVORABLE MODULATION OF HEALTH-RELATED QUALITY AND TEMPORARY PROGRESSION ADJUSTED TO QUALITY RELATED TO HEALTH OF A PATIENT DISEASE AR033465A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/832,752 US20030022811A1 (en) 2001-04-11 2001-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US11848602A 2002-04-08 2002-04-08

Publications (1)

Publication Number Publication Date
AR033465A1 true AR033465A1 (en) 2003-12-17

Family

ID=26816420

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101335A AR033465A1 (en) 2001-04-11 2002-04-11 THE USE OF AN ENDOTHELINE RECEIVER ANTAGONIST IN THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT IN THE FAVORABLE MODULATION OF HEALTH-RELATED QUALITY AND TEMPORARY PROGRESSION ADJUSTED TO QUALITY RELATED TO HEALTH OF A PATIENT DISEASE

Country Status (10)

Country Link
EP (1) EP1379238A1 (en)
JP (1) JP2005503339A (en)
CN (1) CN1514727A (en)
AR (1) AR033465A1 (en)
BR (1) BR0205970A (en)
CA (1) CA2442591A1 (en)
IL (1) IL158071A0 (en)
MX (1) MXPA03009277A (en)
PE (1) PE20021032A1 (en)
WO (1) WO2002085351A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
WO2007133796A2 (en) * 2006-05-15 2007-11-22 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
JP2010536880A (en) 2007-08-22 2010-12-02 ギリード・コロラド・インコーポレーテッド Therapy for diabetic complications
WO2023011596A1 (en) * 2021-08-05 2023-02-09 中国药科大学 Amide compound and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL342500A1 (en) * 1997-08-04 2001-06-04 Abbott Lab Derivatives of pyrolydin-3-carboxylic acid and their application as endothelin antagonists

Also Published As

Publication number Publication date
EP1379238A1 (en) 2004-01-14
IL158071A0 (en) 2004-03-28
CA2442591A1 (en) 2002-10-31
MXPA03009277A (en) 2004-03-10
JP2005503339A (en) 2005-02-03
CN1514727A (en) 2004-07-21
PE20021032A1 (en) 2002-11-12
BR0205970A (en) 2003-09-30
WO2002085351A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
CY1110721T1 (en) Use GLP-2 in combination with other therapeutic agents in bone diseases
CY1105211T1 (en) DRUG COMBINATIONS INVOLVING A P2T RECEPTOR ANTAGONIST AND MELAGATRAN
MXPA05008406A (en) Phenylacetamides and their use as glucokinase modulators.
AR094217A2 (en) 3-Z- MONOETHANOSULFONATE [1- (4- (N - ((4-METHYL-PIPERAZINA-1-IL) -METILCARBONIL) -N-METHYL-AMINO) -ANILINO) -1-PHENYL-METHYLENE] -6- METOXICARBONIL-2-INDOLINONA AND ITS USE AS A MEDICINAL PRODUCT
IS7431A (en) Conjugates of drugs or cytotoxic agents and biologically active peptides
NZ544472A (en) Compounds and therapeutical use thereof
PA8588601A1 (en) COMBINED ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR THE TREATMENT OF CELL PROLIFERATION DISEASES
WO2004059285A3 (en) Tumor killing/tumor regression using cxcr4 antagonists
MX344532B (en) Conveniently implantable sustained release drug compositions.
SI1543063T1 (en) Drug delivery
NO20022065D0 (en) Therapeutic use
AR034213A1 (en) COMPOSITIONS OF DRUGS ON THE BASE OF ANTI-POLINERGIC AGENTS AND INHIBITORS OF PDE-IV
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
ECSP066575A (en) BRADIQUININE B1 RECEIVER ANTAGONISTS
SG146451A1 (en) Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient
CY1108362T1 (en) SPECIFICATION OF X-RAY MEDICINES
AR033465A1 (en) THE USE OF AN ENDOTHELINE RECEIVER ANTAGONIST IN THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT IN THE FAVORABLE MODULATION OF HEALTH-RELATED QUALITY AND TEMPORARY PROGRESSION ADJUSTED TO QUALITY RELATED TO HEALTH OF A PATIENT DISEASE
MX2023000303A (en) Co-agonists at glp-1 and gip receptors suitable for oral delivery.
MXPA05012358A (en) Pharmaceutical combination comprising modafinil and another drug.
TR199902980T2 (en) Use of leptin antagonists for the treatment of diabetes.
PT1713438E (en) Medicinal soap
AR041595A1 (en) THERAPEUTIC TREATMENT
PT1494650E (en) Pharmaceutical formulation comprising melatonin
ECSP045242A (en) Ambroxol for the treatment of painful conditions in the oral and pharyngeal cavity
HUP0302977A2 (en) Methods of treating bone cancer and the pain associated therewith using endothelin antagonists

Legal Events

Date Code Title Description
FA Abandonment or withdrawal